Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,459 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Treatment E Clear all
Completed Not applicable Interventional

Internet-Based, Parent-Led Cognitive-Behavioral Therapy for Anxiety in Youth With ASD

NCT05284435
View directory record Official record
Conditions
Cognitive Behavioral Therapy, Autism Spectrum Disorder, Anxiety Disorder, Obsessive-Compulsive Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder, Specific Phobia
Interventions
Cognitive Behavioral Therapy-Email (iCBT-E), Cognitive Behavioral Therapy-Email and Videoconferencing (iCBT-EV)
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
7 Years to 15 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 2 Interventional Results available

Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy

NCT03418324
View directory record Official record
Conditions
Prostate Cancer
Interventions
TRC105, Abiraterone, Enzalutamide
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Preliminary Efficacy of Lipoxin Analog BLXA4-ME Oral Rinse for the Treatment of Gingivitis

NCT02342691
View directory record Official record
Conditions
Gingival Inflammation
Interventions
BLXA4, Placebo oral rinse
Drug
Lead sponsor
The Forsyth Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection

NCT02378935
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
VOX, SOF/VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
31
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Sep 2, 2026, 5:41 AM EDT
Not listed Phase 1 Interventional

Defined Green Tea Catechin Extract in Preventing Liver Cancer in Participants With Cirrhosis

NCT03278925
View directory record Official record
Conditions
Cirrhosis
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Defined Green Tea Catechin Extract, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pharmacological Study, Questionnaire Administration, Ultrasound
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Sep 2, 2026, 5:41 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neural Mechanisms of Interpersonal Expectations on Negative Affect

NCT06980090
View directory record Official record
Conditions
Negative Affectivity, Non-invasive Brain Stimulation, Placebo Effect, Expectations
Interventions
Session A: Positive Placebo + Active tTIS, Session B: Positive Placebo + Sham tTIS, Session C: Negative Placebo + Active tTIS, Session D: Negative Placebo + Sham tTIS, Session E: On-Placebo + Sham tTIS, Session F: Off-Placebo + Sham tTIS
Behavioral
Lead sponsor
Trustees of Dartmouth College
Other
Eligibility
18 Years to 55 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Hanover, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 2, 2026, 5:41 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

NCT02339740
View directory record Official record
Conditions
Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
Interventions
Arsenic Trioxide, Cytarabine, Dexamethasone, Idarubicin, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration, Tretinoin
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 21 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
152
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 121 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 2, 2026, 5:41 AM EDT
Recruiting Phase 3 Interventional

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

NCT03959085
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
Interventions
Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Pegaspargase, Positron Emission Tomography, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, Vincristine Sulfate
Procedure · Biological · Drug + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
365 Days to 25 Years
Enrollment
5,951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
203
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 2, 2026, 5:41 AM EDT
Active, not recruiting Phase 2 Interventional

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

NCT06001385
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Neoplasm, Lymphoma, Chronic Myelomonocytic Leukemia, Pro-Lymphocytic Leukemia, Myelofibrosis
Interventions
Busulfan, Fludarabine, PBSC Hematopoietic Stem Cell Transplantation (HSCT), Post-Transplant Cyclophosphamide, Mesna, Tacrolimus, Mycophenolate Mofetil, Patient Reported Outcomes, Melphalan, Total-body irradiation, Cyclophosphamide
Drug · Procedure · Other + 1 more
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
32
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pre-Study of Wild Type Enterotoxigenic E. Coli (ETEC) Strain for Verification of a Planned Challenge Dose

NCT06290089
View directory record Official record
Conditions
ETEC Diarrhea
Interventions
Enterotoxigenic E. coli (ETEC) strain
Other
Lead sponsor
Scandinavian Biopharma AB
Industry
Eligibility
18 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults

NCT01458054
View directory record Official record
Conditions
Hepatitis C
Interventions
Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose), Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients

NCT00089466
View directory record Official record
Conditions
HIV Infections
Interventions
AMD11070
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
3
States / cities
Birmingham, Alabama • Atlanta, Georgia • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

NCT01874054
View directory record Official record
Conditions
Hodgkin Disease
Interventions
brentuximab vedotin, bendamustine
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
13
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Sep 2, 2026, 5:41 AM EDT
Terminated Phase 2 Interventional Results available

Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma

NCT00942422
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
Interventions
defined green tea catechin extract, gene expression analysis, protein analysis, laboratory biomarker analysis
Dietary Supplement · Genetic · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Sep 2, 2026, 5:41 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Stepped Care Approach to Treating Dental Fear

NCT06024395
View directory record Official record
Conditions
Dental Fear
Interventions
A stepped-care approach to the treatment of dental fear; Dental Fearless
Behavioral
Lead sponsor
New York University
Other
Eligibility
13 Years to 99 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 2, 2026, 5:41 AM EDT
Not listed Not applicable Interventional

Evaluation of the Wear of Vitamin E Treated Polyethylene Components in Primary THA Using RSA

NCT00551967
View directory record Official record
Conditions
Osteoarthritis of Hip, Traumatic Arthritis of Hip
Interventions
Hip replacement
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Not applicable Interventional Results available

Treatment of External Genital Warts With Cryotherapy and Sinecatechins 15% Ointment

NCT02147353
View directory record Official record
Conditions
External Genital Warts
Interventions
Sinecatechins 15% Ointment, Cryotherapy alone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants

NCT06877702
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986460
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Not applicable Interventional

Virtual White Boards for Patient Satisfaction

NCT04497922
View directory record Official record
Conditions
Satisfaction, Patient, Covid19, Emergencies, Satisfaction, Information Disclosure
Interventions
e-ink screen, Treatment as usual
Device · Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 2, 2026, 5:41 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

NCT02711137
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 2, 2026, 5:41 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane

NCT05146739
View directory record Official record
Conditions
Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myelodysplastic Syndrome
Interventions
Cytarabine, Fludarabine, Leucovorin, Triple Intrathecal Chemotherapy, Uproleselan
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 2, 2026, 5:41 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Decision Algorithm for Vital Sign Assessment in the Outpatient Physical Therapy Setting

NCT07258030
View directory record Official record
Conditions
Healthy
Interventions
E-Delphi
Other
Lead sponsor
Youngstown State University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Not applicable Interventional Results available

Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19

NCT05419128
View directory record Official record
Conditions
Alcohol Use Disorder, Family Members, Behavior, Addictive
Interventions
PartnerCHESS, ACHESS
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Not applicable Interventional Results available

Brief Interventions for Short-Term Suicide Risk Reduction in Military Populations

NCT02042131
View directory record Official record
Conditions
Suicide, Suicidal Ideation
Interventions
Treatment As Usual (TAU), Standard Crisis Response Plan (S-CRP), Enhanced Crisis Response Plan (E-CRP)
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 2, 2026, 5:41 AM EDT